0001104659-26-059756
SEC filingProtalix delivered transformative Q1 2026 results with revenue surging 233.7% to $33.8M, driving $18.3M net income and $0.22 EPS versus prior-year losses, fueled by high-margin contributions amid goods sales timing shifts.
Protalix BioTherapeutics reported exceptional Q1 2026 financial performance, marked by revenue of $33.8 million, up 233.7% from $10.1 million in Q1 2025. This surge propelled gross profit to $29.6 million, a 1432.5% increase from $1.9 million, yielding an 87.8% gross margin—substantially higher than implied prior-year levels. The revenue growth reflects partner dynamics, where the total decrease in revenues from selling goods was partially offset by an increase in sales to Chiesi. Sales of Elfabrio to Chiesi may not directly mirror patient demand, as these represent fulfilled orders to Chiesi's inventory, introducing variability tied to ordering patterns.
Operating income flipped to a $21.1 million profit from a $4.1 million loss, achieving a 62.7% operating margin and 610.2% YoY growth. This efficiency underscores controlled expense growth relative to top-line expansion, supporting net income of $18.3 million (606.1% YoY) and diluted EPS of $0.22 (540.0% YoY), reversing Q1 2025 losses. The decrease in sales to Fiocruz resulted from delivery timing, while periods of no orders from Pfizer may occur due to inventory de-stocking or other factors. Chiesi's ordering is not expected to change until Elfabrio demand stabilizes, launch matures, and market share grows in the US and internationally.
Looking forward, the Company anticipates significant R&D expenditures as efforts expand for current and future product candidates, including preregistration activities. Goods sales volatility from partners like Fiocruz, Pfizer, and Chiesi highlights execution risks, but robust margins and cash flow position Protalix to fund pipeline advancement while maintaining a fortified balance sheet.